比索洛尔联合厄贝沙坦治疗慢性心力衰竭患者的临床效果

Clinical effect of Bisoprolol combined with Irbesartan in the treatment of patients with chronic heart failure

目的分析比索洛尔联合厄贝沙坦治疗慢性心力衰竭患者的临床效果。方法选择2018年7月~2019年7月我院收治的88例慢性心力衰竭患者作为研究对象,根据入住病床号的单双数,分为治疗组(44例)和对照组(44例),对照组给予厄贝沙坦治疗,治疗组应用比索洛尔联合厄贝沙坦治疗,比较两组患者的心功能指标、血压及血清B型脑钠肽(BNP)及超敏C-反应蛋白(hs-CRP)水平。结果治疗组治疗后的左心射血分数(LVEF)水平高于对照组,差异有统计学意义(P<0.05),治疗组左心室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)水平低于对照组,差异有统计学意义(P<0.05);治疗组治疗后的BNP、hs-CRP水平低于对照组,差异有统计学意义(P<0.05);治疗组治疗后的收缩压(SBP)、舒张压(DBP)、脉压差低于对照组,差异有统计学意义(P<0.05);治疗组的治疗总有效率高于对照组,差异有统计学意义(P<0.05)。结论比索洛尔联合厄贝沙坦治疗,对于治疗慢性心力衰竭效果确切,可有效改善患者心功能指标、血压水平及血清BNP、hs-CRP水平,在临床中有较高的应用价值。

Objective To analyze the clinical effect of Bisoprolol combined with Irbesartan on patients with chronic heart failure.Methods A total of 88 patients with chronic heart failure admitted to our hospital from July 2018 to July 2019 were selected as research objects.According to the single or even number of hospital beds,they were divided into treatment group(44 cases)and control group(44 cases).The control group was treated with Irbesartan.The treatment group was treated with Bisoprolol and Irbesartan.The cardiac function index,blood pressure,serum B-type brain natriuretic peptide(BNP)and high sensitivity C-reactive protein(hs-CRP)levels of the two groups were compared.Results The left ventricular ejection fraction(LVEF)level in the treatment group was higher than that in the control group,with statistical significance(P<0.05),while the left ventricular end diastolic diameter(LVEDD)and left ventricular end systolic diameter(LVESD)levels in the treatment group were lower than those in the control group,with statistical significances(P<0.05).The levels of BNP and hs-CRP in the treatment group were lower than those in the control group after treatment,and the differences were statistically significant(P<0.05).The systolic blood pressure(SBP),diastolic blood pressure(DBP)and pulse pressure difference after treatment in the treatment group were lower than those in the control group,with statistically significant differences(P<0.05).The total effective rate of the treatment group was higher than that of the control group,with statistically significant difference(P<0.05).Conclusion The combination of Bisoprolol and Irbesartan has definite effect on the treatment of chronic heart failure,which can effectively improve the cardiac function index of patients,regulate the blood pressure level of patients,optimize the serum BNP and hs-CRP levels of patients,and has higher application value in clinical practice.